Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
暂无分享,去创建一个
R. Greil | J. Gribben | I. Flinn | Carol Moreno | A. Tedeschi | M. Šimkovič | D. Gill | L. Styles | L. Larratt | B. Anz | Zhengyuan Wang | L. Cheung | A. Nguyen | Cathy Zhou | F. Demirkan | C. Moreno